OBJECTIVE: Certain drugs used in the treatment of patients with anxiety disorders can interact with other psychotropic drugs and with pharmacological treatments for physical illnesses. There is a need for an updated comparative review of clinically relevant drug interactions in this area. DESIGN: Relevant literature on drug interactions with medications used in the treatment of anxiety disorders was identified through a search in MEDLINE and EMBASE. RESULTS: Drug interactions involving medications used to treat anxiety disorders may be pharmacokinetic, such as enzyme inhibition or induction in the cytochrome P450 system and transporter-mediated drug interactions, or pharmacodynamic, such as additive effects in causing drowsiness or additive effects at neurotransmitter receptors. Certain selective serotonin reuptake inhibitors (fluoxetine, fluvoxamine, and paroxetine) are particularly liable to be potentially involved in untoward pharmacokinetic interactions. CONCLUSIONS: The potential for drug interactions with medications used in anxiety disorders should be the cause of clinical concern, particularly in elderly individuals. However, the liability for harmful drug interactions may be anticipated, and the risk reduced. Although not all interactions are clinically relevant, careful monitoring of clinical response and possible interactions is essential.
OBJECTIVE: Certain drugs used in the treatment of patients with anxiety disorders can interact with other psychotropic drugs and with pharmacological treatments for physical illnesses. There is a need for an updated comparative review of clinically relevant drug interactions in this area. DESIGN: Relevant literature on drug interactions with medications used in the treatment of anxiety disorders was identified through a search in MEDLINE and EMBASE. RESULTS: Drug interactions involving medications used to treat anxiety disorders may be pharmacokinetic, such as enzyme inhibition or induction in the cytochrome P450 system and transporter-mediated drug interactions, or pharmacodynamic, such as additive effects in causing drowsiness or additive effects at neurotransmitter receptors. Certain selective serotonin reuptake inhibitors (fluoxetine, fluvoxamine, and paroxetine) are particularly liable to be potentially involved in untoward pharmacokinetic interactions. CONCLUSIONS: The potential for drug interactions with medications used in anxiety disorders should be the cause of clinical concern, particularly in elderly individuals. However, the liability for harmful drug interactions may be anticipated, and the risk reduced. Although not all interactions are clinically relevant, careful monitoring of clinical response and possible interactions is essential.
Authors: Jeffrey J Sutherland; Thomas M Daly; Xiong Liu; Keith Goldstein; Joseph A Johnston; Timothy P Ryan Journal: PLoS One Date: 2015-03-04 Impact factor: 3.240
Authors: Víctor Micó; Rodrigo San-Cristobal; Roberto Martín; Miguel Ángel Martínez-González; Jordi Salas-Salvadó; Dolores Corella; Montserrat Fitó; Ángel M Alonso-Gómez; Julia Wärnberg; Jesús Vioque; Dora Romaguera; José López-Miranda; Ramon Estruch; Francisco J Tinahones; José Lapetra; J Luís Serra-Majem; Aurora Bueno-Cavanillas; Josep A Tur; Vicente Martín Sánchez; Xavier Pintó; Miguel Delgado-Rodríguez; Pilar Matía-Martín; Josep Vidal; Clotilde Vázquez; Ana García-Arellano; Salvador Pertusa-Martinez; Alice Chaplin; Antonio Garcia-Rios; Carlos Muñoz Bravo; Helmut Schröder; Nancy Babio; Jose V Sorli; Jose I Gonzalez; Diego Martinez-Urbistondo; Estefania Toledo; Vanessa Bullón; Miguel Ruiz-Canela; María Puy- Portillo; Manuel Macías-González; Nuria Perez-Diaz-Del-Campo; Jesús García-Gavilán; Lidia Daimiel; J Alfredo Martínez Journal: Front Endocrinol (Lausanne) Date: 2022-09-06 Impact factor: 6.055